
|
|
 |
One of the first facilities of its kind in the country, we continue to pioneer applications of diagnostic DNA-based testing for:
- Neoplastic disease
- Orphan diseases
- DNA repair disorders
- Prenatal evaluation
|
|
|
- Friedreich ataxia
- Fusion gene quantitation for disease monitoring in leukemias
- Oncogene mutation analysis in solid tumors as companion diagnostics for targeted molecular therapies
- DNA fingerprinting for determination of paternity, twin zygosity and surgical specimen identity
- Detection of clonal immunoglobulin and T-cell receptor gene rearrangements in lymphomas and leukemias
- Differentiation of donor from recipient cells after bone marrow or organ transplant by DNA polymorphisms
Dedicated to disorders too rare to be of interest to general reference laboratories, we offer a way to transfer both the regulatory and workload burdens from the research setting to a licensed clinical laboratory.
- We provide validated confirmation of mutations identified in research laboratories which can then be reported directly to physicians and patients who request such information for clinical decision-making. This service will be especially beneficial for individuals and families who have been identified as mutation carriers by a research laboratory.
- We will confirm mutations in a fresh sample (blood, saliva, or cheek swab) from the proband or other known carriers, such as the parents. After a mutation is confirmed, diagnostic, prenatal, and carrier testing is available for other at-risk family members.
Mutation detection, carrier testing and prenatal diagnosis
- Western Blot for DNA Repair Protein Expression
- Ataxia Telangiectasia, A-T (ATM)
- Nijmegen Breakage Syndrome (NBN)
- A-T-like Disorder (MRE11)
- NBS-like Disorder (RAD-50)
- Fanconi Anemia (FANC D1, A, B, C, E, F, G, L and M)
- Radiation Sensitivity/Colony Survival Assay
- Rapid Functional Flow Cytometry SMC1 Assay for Ataxia Telangiectasia (A-T) proband and carrier screening
We offer prenatal testing for known familial variants in any gene
- Assessment of maternal cell contamination
- Comparison to parental/familial controls
- Analysis of single base changes as well as some microdeletions previously confirmed in a parent by sequencing
- Communication with referring physician or genetic counselor
A complete menu of testing for a growing variety of genetic and neoplastic diseases is available upon request.
In addition to our many clinical services, we maintain an active role in basic and applied clinical research. |
|
|
|
|
 |
Gau, C.-L., R.A. Rosenblatt, V. Cerullo, F.D. Lay, A.C. Dow, J. Livesay, N. Brunetti-Pierri, B. Lee, S.D. Cederbaum, W.W. Grody and G. Lipshutz. Short-term correction of arginase deficiency in a neonatal murine model with a helper-dependent adenoviral vector. Molec. Ther. 2009; 17: 1155-1163. |
 |
Rosove, M.H. and W.W. Grody. Should we be applying warfarin pharmacogenetics to clinical practice? No, not now. . Ann. Intern. Med. 2009; 151: 270-273. |
 |
Mumenthaler, S.M., H. Yu, S. Tze, S.D. Cederbaum, A.E. Pegg, D.B. Seligson and W.W. Grody. . Differential expression of arginase II in androgen-dependent versus androgen-independent prostate cancer.. Int. J. Oncol. 2008; 32: 357-365. |
|
|